Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
May 31 SNY FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31 SNY FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
May 31 SNY Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
May 31 SNY Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
May 31 SNY Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
May 31 SNY Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
May 31 SNY Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31 SNY Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31 SNY Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 30 SNY Press Release: Sanofi completes acquisition of Inhibrx, Inc.
May 29 SNY VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3
May 29 SNY Sanofi’s CEO is giving OpenAI access to its data in the hope of developing drugs more quickly
May 29 SNY 3 High-Yielding Dividend Stocks On Euronext Paris With Up To 4.2% Yield
May 28 SNY FDA accepts Sanofi’s Sarclisa sBLA for priority review
May 27 SNY Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
May 27 BMRN BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the stock a year ago
May 27 SNY Sanofi's Sarclisa gets accepted for FDA priority review for treatment of multiple myeloma
May 27 SNY Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags